產品詳情
簡單介紹：
Anti-PROSC抗體產品質量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PROSC抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-PROSC
Cat. Number:
Anti-PROSC抗體KL-19184R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PROSC is a 275 amino acid ubiquitously expressed enzyme that is highly conserved from bacteria to mammals. The gene encoding Anti-PROSC抗體PROSC is cotranscribed with proline sythetase. PROSC requires the cofactor pyridoxal phosphate, the active form of vitamin B6 that acts in all transamination reactions. The PROSC gene maps to human chromosome 8, which is made up of nearly 146 million bases and encodes about 800 genes. Translocation of portions of chromosome 8 with amplifications of the c-Myc gene are found in some leukemias and lymphomas, and are typically associated with a poor prognosis. Portions of chromosome 8 have been linked to schizophrenia and bipolar disorder. Chromosome 8 is also associated with Pfeiffer syndrome, congenital hypothyroidism and Waardenburg syndrome.
Also known as:
FLJ11861; Proline synthase Anti-PROSC抗體co-transcribed bacterial homolog protein; Proline synthetase co transcribed bacterial homolog; Proline synthetase co transcribed homolog (bacterial); PROSC; PROSC_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Anti-PROSC抗體Pig, Guinea Pig, Cat, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PROSC.
●
Predicted Molecular Weight: 30kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PROSC抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
